Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 303-312

  Berman, Robert M ^a   Thase, Michael E ^b   Trivedi, Madhukar H ^c   Hazel, James A ^a   Marler, Sabrina Vogel ^a   McQuade, Robert D ^d   Carson, William ^d   Baker, Ross A ^a   Marcus, Ronald N ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Adjunctive aripiprazole; Antidepressant therapy; Longterm safety and tolerability; Major depressive disorder

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GLUCOSE; LIPID; MIRTAZAPINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OUTCOME ASSESSMENT; PARKINSONISM; RATING SCALE; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; WEIGHT GAIN;

EID: 80053626849     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S18333     Document Type: Article

References (28)

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D Report. Am J Psychiatry. 2006;163(11):1905-1917.
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
3. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: A literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006; 75(3):139-153.
4. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 2nd ed. Arlington, VA: American Psychiatric Association; 2000.
5. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
6. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
7. Berman R, Fava M, Thase M, et al. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
8. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebocontrolled trials. Schizophr Res. 2003;61(2-3):123-136.
9. Marcus RN, Carson WH, McQuade RD, et al. Overview of safety and tolerability of aripiprazole in acute mania. Paper presented at the annual meeting of the American Psychiatric Association, May 1-6, 2004, New York, NY.
10. M. Weight gain and antidepressants. J Clin Psychiatry. 2000; 61 Suppl 11:37-41.
11. Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: A survey of 500 US psychiatrists. Psychopharmacol Bull. 2007;40(2):22-37.
12. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10): 1289-1297.
13. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31(11):2505-2513.
14. Thase ME, Corya SA, Osuntokun O, et al. A randomized, doubleblind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
17. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-659.
18. M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. Guy W. Clinical Global Impressions (CGI). In: US Department of Health, Education, and Welfare Publication (ADM) 76-338. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976.
20. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
21. TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
22. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: US Department of Health, Education, and Welfare publication (ADM)76-338. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976.
23. Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: A pooled post hoc analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry. 2009;11(6):344-352.
24. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. J Clin Psychopharmacol. 2007;27(6):639-661.
25. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156(8): 1170-1176.
26. Wise TN, Perahia DG, Pangallo BA, Losin WG, Wiltse CG. Effects of the antidepressant duloxetine on body weight: Analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006;8(5): 269-278.
27. Wade A, Despiegel N, Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry. 2006; 18(2):83-89.
28. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14(3):175-182.